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Abstract  
Patellar tendinopathy (PT) is a debilitating condition that often 
affects those who are physically active. Gene variation is known 
to contribute to human tendinopathy but the role of DNA methyl-
ation, as an epigenetic factor, has only recently been discovered. 
Using a case-control approach, we sought to determine whether 
differences existed between the methylation status of the MMP11 
gene promoter in patellar tendinopathy compared to healthy ten-
don. We used PCR and pyrosequencing to interrogate the meth-
ylation profiles of 4 CpG sites (areas of the genome rich in C/G 
nucleotides) upstream of the MMP11 gene in DNA from males 
with PT (n = 10) and those with healthy tendon (n = 10). We also 
conducted a correlation analysis to establish whether age influ-
enced methylation in the PT patients and controls. We found a 
significant (p = 0.045) difference in the methylation status of a 
single CpG site 65 base pairs (bp) upstream of the MMP11 pro-
moter between the PT group and controls. There were no other 
differences in the extent of MMP11 promoter methylation be-
tween the two groups. Interestingly, we also found that in controls 
the degree of methylation at a second CpG site, 55 bp upstream 
of the first exon, tentatively correlated (r = 0.77, p = 0.009) with 
age. However, the correlation did not reach significance when a 
potential outlier was removed. This is the first study to show an 
epigenetic alteration to a member of the MMP gene family in hu-
man patellar tendinopathy. The data add to our understanding of 
how epigenetics should be considered when developing appropri-
ate risk models. 
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Introduction 
 
Patellar tendinopathy (PT), is an exercise-associated injury 
that results in significant disability and can compromise the 
career of an athlete (Peers and Lysens, 2005). The preva-
lence of PT is high in sports, such as volleyball (44.6% ± 
6.6%) and basketball (31.9% ± 6.8%) (Lian et al., 2005) 
and it accounts for up to 15% of the soft tissue injuries re-
ported in military cohorts (Rutland et al., 2010). Recently, 
a study by Bode et al. (2017) found prevalence rates as high 
as 13.4% in young elite level soccer players (Bode et al., 
2017). Furthermore, in addition to the type of sports partic-
ipation, the duration of training, female gender and ham-
string flexibility have all been shown to affect the risk of 
PT (Morton et al., 2017). There is also some evidence to 
suggest that both back pain and a family history of tendon 
problems might be related to the risk of PT (Morton et al.,  
2017).  
From a histological perspective, the development of 
PT is associated with neovascularisation, an increase in 
collagen type III fibers and an accumulation of glycosa-
minoglycans (Rosso et al., 2015). Such changes may, in 
part, be due to the altered expression of matrix metallopro-
teinase (MMP) enzymes that have been shown to have an 
important role in regulating tendon extracellular matrix 
(ECM) homeostasis (Del Buono et al., 2013). Interestingly, 
genetic variation within genes (like the MMPs), that code 
for enzymes that regulate ECM homeostasis, are known to 
impact on Achilles tendinopathy risk (Raleigh and Collins, 
2012; Collins and Raleigh, 2009). However, genetic asso-
ciation studies conducted to identify risk variants have 
sometimes yielded conflicting data. For example, Raleigh 
et al. (2009) demonstrated that the G allele of the rs679620 
variant within the MMP3 gene increased the risk of Achil-
les tendinopathy in a South African study, whereas the 
same variant in a British cohort did not increase risk (El 
Khoury et al., 2016). Likewise, the COL5A1 rs12722 T 
variant has been shown to increase risk of Achilles tendi-
nopathy in both South African and Australian cohorts (Sep-
tember et al., 2009) but in British Caucasians this variant 
does not modify risk (Brown et al., 2017).  
We recently suggested that epigenetic modifica-
tions, such as DNA methylation, might explain discrepant 
association signals sometimes obtained in studies on hu-
man patellar tendinopathy (El Khoury et al., 2018). Indeed, 
we demonstrated that methylation changes to a CpG site 
upstream of the ADAMTS4 promoter were associated with 
patellar tendinopathy (El Khoury et al., 2018). However, to 
date, and as far as we are aware, no other research has been 
published to address the impact of DNA methylation on the 
risk of human tendinopathy. 
The MMP11 enzyme catalytically degrades several 
components of the extracellular matrix (ECM) including 
aggrecan, fibronectin and laminin (Araki and Mimura, 
2017). Although the detailed role that MMP11 plays in 
ECM homeostasis is poorly understood, the expression of 
MMP11 in Achilles tendinopathy is substantially affected. 
For example, it has been shown that MMP11 RNA levels 
are both five and six-fold higher in painful and ruptured 
Achilles tendon respectively, compared to control tissue 
(Jones et al., 2006). Furthermore, MMP11 expression de-
creases nearly twofold in human Achilles tenocytes that 
have been subjected to mechanical strain (Jones et al., 
2013). Although these observations may infer a role for 
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MMP11 in tendinopathy, the mechanisms underlying the 
observations are unknown.  
The MMP11 gene was originally mapped to chro-
mosome 22 (Anglard et al., 1995). Multiple transcripts are 
encoded within the region 24,110,413-24,126,503 
(GRch37-hp19 at: https://grch37.ensembl.org/index.html) 
and expression is known to be altered by DNA methylation 
(Navarro et al., 2012). Specifically, hypomethylation is as-
sociated with transcriptional upregulation of MMP11 (Na-
varro et al., 2012). With this in mind, we hypothesized that 
the methylation status of the MMP11 promoter might differ 
in DNA isolated from patellar tendinopathy compared to 
normal tendon. If this were the case, such differences in 
methylation might explain why MMP11 expression is sub-
stantially altered in tendinopathy and lead the way to novel 
strategies that could reduce the incidence of these injuries. 
 
Methods 
 
Patellar tendon tissue was obtained from 10 males with 
healthy patellar tendons (CON) and 10 males with patellar 
tendinopathy (PT). The CON samples were from patients 
undergoing ACL reconstruction surgeries using a patellar 
tendon graft and had no history of tendinopathy. Controls 
also had magnetic resonance imaging (MRI) to confirm 
their injury. The PT samples were from patients undergo-
ing surgical debridement for recalcitrant overuse patellar 
tendinopathy (Parkinson et al., 2010). The PT specimens 
all had ultrasound scans (US) or MRI confirmation of the 
diagnosis by a medical doctor. PT samples were taken from 
the proximal tendon. Normal (CON) tendons were also 
taken from the proximal end, at the margins of the graft. 
Participants were Caucasian, aged from 19 to 41 years and 
they were all otherwise healthy. All participants provided 
written informed consent and approval for this study was 
obtained from the University of Northampton’s School of 
Health Research Ethics Committee.  
We originally extracted, and bisulfite treated, the 
DNA from these samples as described in our previous 
study (El Khoury et al., 2018). Hence for this study we re-
interrogated the same DNA samples using a pyrosequenc-
ing assay specific for the MMP11 gene 
(Hs_CHCHD10_01_PM) promoter that was selected from 
the Pre-Designed PyroMark® CpG Assays (Qiagen, Hil-
den, Germany). Using this assay, we measured the methyl-
ation statuses of 4 separate CpG sites that were -38 (CpG 
1), -55 (CpG 2), -58 (CpG 3) and -65 (CpG 4) bp respec-
tively from the first exon of the MMP11 gene (transcript 
003, GRch37, hg19).  
The bisulfite treated DNA samples were amplified 
on a Techne TC-512 thermocycler (Bibby Scientific Ltd, 
Staffordshire, UK), using the PCR primer sets of the Pyro-
Mark® CpG Assay. This amplified the specific region of 
interest (141 bp amplicon product) within the MMP11 gene 
promoter at 31 bp from the first exon. PCR amplification 
was confirmed by running the products on a 1x agarose gel 
alongside a GeneRulerTM 100 bp ladder (MBI Fermentas, 
UK). 
 
Following gel electrophoresis, the biotinylated PCR 
products were immobilized to Streptavidin-coated Se-
pharose high-performance beads (GE Healthcare, Buck-
inghamshire, UK). The PyroMark® Q24 vacuum (Qiagen, 
Hilden, Germany) was used to capture the immobilized 
PCR products, before releasing them into a 24 well Pyro-
Mark® Q24 plate containing 1x sequencing primer diluted 
in 25 μl PyroMark® Annealing Buffer. In order for the se-
quencing primer to anneal to samples, the PyroMark® Q24 
plate was placed on a hot-plate at 80 °C for 2 min, followed 
by 10 min incubation at room temperature. The samples 
were then loaded into the PyroMark® Q24 for pyrose-
quencing. Each run included hypo and hyper methylated 
DNA control samples. 
We used PyroMark® Q24 (Version 2.0.6) software 
to analyse the percent methylation of each CpG site in both 
PT and CON groups. An independent samples t-test was 
used to establish whether significant differences (p<0.05) 
existed between each CpG site in PT and CON groups, 
based on a normal distribution of our data. We also deter-
mined the effect of age on methylation status by conduct-
ing a Pearson’s correlation analysis for each CpG site in 
the PT, CON and combined groups. All data analyses were 
performed using SPSS Version 20 (IBM Corp. Armonk, 
NY). 
 
Results 
 
The recruited CON and PT groups were similarly matched 
for age (p = 0.449). Typical pyrograms showing the per-
centage DNA methylation at the 4 CpG cites within the 
MMP11 gene promoter (panels A and B) are shown in Fig-
ure 1. We found a significant difference (p = 0.045) in 
DNA methylation between the CON and PT group at the 
CpG 4 site that sits 65 bp upstream of the MMP11 first 
exon (Figure 2). At this CpG site, the mean percentage 
methylation in the PT samples was 4.8 ± 0.4 (95% CI 3.98 
to 5.66) compared to the CON value of 3.6 ± 0.4, (95% CI 
2.88 to 4.33). The affect size (Cohens d) for this difference 
was 0.966. We were unable to quantify the methylation sta-
tus at CpG site 3 in both the CON and PT groups as the 
data did not meet an acceptable quality control standard. 
The reason for this, at present, is unknown. Finally, we 
found no additional differences in methylation status, for 
each CpG site measured, between the CON and PT groups. 
In addition, for the CON group, we found a tentative 
correlation (r = 0.77; p = 0.009) between participant age 
and degree of methylation at the CpG 2 site (Figure 3A). 
However, the correlation failed to reach significance (p > 
0.05) when a potential outlier was removed. By compari-
son there was no correlation (r = 0.11; p = 0.764) between 
participant age and degree of methylation at the CpG 2 site 
in the PT group (Figure 3B). Furthermore, there were no 
other correlations between age and degree of methylation 
at any of the other CpG sites measured in both the CON 
and PT groups. Indeed, when the analyses were pooled to 
contain both groups, there were no additional correlations. 
The mean age of the CON and PT groups was 25.1 ± 6.4 
and 23.2 ± 4.4 years respectively. 
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 Figure 1 (Panel A-B). Typical Pyrograms showing methylation status at CpG sites within the MMP11 gene promoter from 
control and PT samples. The CpG sites are shown shaded in blue/grey with the percentage (%) methylation above each site. Yellow shaded areas 
are bisulfite controls. Panel A) Percentage methylation at four CpG sites within the MMP11 gene promoter from a CON sample. Panel B) Percentage 
methylation at four CpG sites within the MMP11 gene promoter from a PT sample. Sites from left to right are: -38 (CpG 1), -55 (CpG 2), -58 (CpG 3) 
and -65 (CpG 4) bp respectively from the first exon of the MMP11 gene. 
 
 
 
 
Figure 2. Comparison of the mean DNA methylation between 
the CON and PT groups within the promoter region of the 
MMP11 gene. Sites are: -38 (CpG 1), -55 (CpG 2) and -65 (CpG 4) bp 
respectively from the first exon of the MMP11 gene. Bars represent mean 
(%) ± standard error of the mean (SEM). CON, white bars and PT, shaded 
bars. *, p = 0.045. 
 
Discussion 
 
We have shown a statistically significant difference (p = 
0.045) in DNA methylation at a CpG site (CpG 4) in the 
MMP11 gene promoter in patellar tendinopathy, compared 
to controls. This CpG site lies 65 bp upstream of the 
MMP11 gene and showed higher methylation in the PT 
group. At present we do not know why this change takes 
place but methylation changes to the MMP11 gene are 
known to alter MMP11 RNA expression levels (Navarro et 
al., 2012). For example, hypomethylation causes an in-
crease in MMP11 (Navarro et al., 2012). Indeed, it is pos-
sible that hypomethylation of the MMP11 gene promoter 
may, in part, explain the elevated levels of MMP11 mRNA 
expression previously observed in both ruptured and pain-
ful Achilles tendon (Jones et al., 2006) compared to normal 
tendon. 
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 Figure 3. A) Correlation between age and degree of DNA 
methylation at CpG 2 in the CON group (r = 0.77, p = 0.009). 
B) Lack of correlation between age and degree of DNA meth-
ylation at CpG site 2 in the PT group (r = 0.11, p = 0.764). 
CpG 2 is 55 bp upstream of the MMP11 TSS. 
 
Interestingly, we found a hypermethylation (not hy-
pomethylation) event within the MMP11 promoter in PT 
samples compared to controls. Hypermethylation is typi-
cally associated with reduced gene expression (Roach et 
al., 2005). Therefore it might be expected that MMP11 sub-
strates accumulate within PT, as the amount of MMP11 en-
zyme available for catalysis would become limited. Indeed, 
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proteoglycan accumulation has been observed in PT. Spe-
cifically, Parkinson and colleagues found increased levels 
of proteoglycans such as aggrecan in the tendon samples 
from patients that were used in this study (Parkinson et al., 
2011). Normally aggrecan can protect tendon from damage 
as it binds to water molecules, aiding hydration and reduc-
ing the effect of over compression (Riley, 2004; Cook and 
Purdam, 2012). However over-hydration can lead to swell-
ing in tendinopathy (Parkinson et al., 2011) and it is possi-
ble that hypermethylation of the MMP11 promoter might 
exacerbate this process. 
It is interesting that we found a tentative correlation 
between age and degree of methylation at CpG site 2 that 
sits 55 bp upstream of the MMP11 first exon. This correla-
tion was apparent in the CON group but not in DNA from 
those with PT. However, this result must be considered 
preliminary as when we removed a potential outlier from 
the data set the correlation disappeared. Although we can-
not yet comment on the significance of this finding, it is 
possible that an increase in methylation in the promoter of 
the MMP11 gene might be necessary to allow for ECM 
adaptions as a person ages. Therefore, the lack of correla-
tion between age and CpG methylation observed by us in 
the PT group may indicate an abnormal promoter methyl-
ation pattern that precedes tendinopathy. However, this 
will need to be verified by additional research. 
In this study, we looked at the methylation statuses 
of several CpG sites upstream of the MMP11 gene in DNA 
from males with PT and compared them to controls. We 
found a significant difference (hypermethylation) in the 
methylation profile between these two groups for the CpG 
site 4 that is -65 bp away from the start of the gene. Alt-
hough most studies relating to DNA methylation in mus-
culoskeletal disorders report more extensive methylation 
changes over numerous CpG rich regions (Reynard, 2017), 
there is compelling evidence that methylation changes at 
single CpG sites can also have profound effects. For exam-
ple, we have previously shown that methylation change at 
a single CpG site within the ADAMTS4 gene promoter also 
associates with PT (El Khoury et al., 2018). Furthermore, 
Nile and colleagues (2008) have shown that single CpG 
site methylation changes alter interleukin-6 expression, 
which impacts on the pathogenesis of rheumatoid arthritis 
(Nile et al., 2008). Methylation of single CpG sites up-
stream of the SLC23A and NCOR2 genes are also known 
to influence the severity of spinal muscular atrophy 
(Zheleznyakova et al., 2015).   
Although we have shown that the degree of methyl-
ation, at a single CpG site -65 bp away from the start of the 
MMP11 gene differs in patellar tendinopathy compared to 
healthy tendons our study does have limitations. Firstly, as 
we only had access to a limited amount of sample for each 
patient we were unable to measure the mRNA expression 
levels of MMP11. However, previous studies have shown 
that MMP11 promoter methylation does influence its ex-
pression (Navarro et al., 2012; Veerla et al., 2008). Sec-
ondly, we only investigated a small section of the promoter 
for MMP11 transcript 003 and additional work should fo-
cus on other regions. Thirdly, the clinical samples available 
for this study were from a small group of male Caucasians 
and the same results might not be obtained in female or 
non-Caucasian groups. Indeed, we would recommend re-
peating this study in different population cohorts to estab-
lish whether similar DNA methylation events are observed 
across populations. Finally, although there were no differ-
ences between age in our PT and control groups, we were 
unable to control for both weight and height as these data 
were not available to us at the time of sampling.  
 
Conclusion 
 
We provide the first preliminary data that suggests DNA 
methylation of a member of the MMP family of genes dif-
fers in patellar tendinopathy compared to healthy tendon. 
Our data add to our earlier work on the epigenetics of hu-
man tendinopathy and suggest that risk assessment, on the 
basis of genetics alone, is incomplete without a knowledge 
of epigenetic factors. 
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Key points 
 
 An understanding of the epigenetics of tendinopathy 
leads the way to possible future preventative strate-
gies, as epigenetic factors can be modified by the 
environment. Hence, we speculate that specific 
changes to training, diet and possibly training sur-
face and climate, informed by epigenetics, could re-
duce incidence of these injuries. 
 DNA methylation changes, including those reported 
here in the MMP11 gene promoter, may partially ex-
plain the different patterns of genetic risk factors 
that are sometimes observed between different pop-
ulation cohorts. 
 DNA methylation patterns coupled with genomic 
factors and other epigenetic markers, such as 
miRNA expression profiles, will improve current 
risk models for tendinopathy.  
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